Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8536 to 8550 of 8915 results

  1. Physical activity and the environment (PH8)

    This guideline has been updated and replaced by NICE guideline NG90.

    Withdrawn guideline

  2. Community engagement (PH9)

    This guidance has been updated and replaced by NICE guideline NG44.

    Withdrawn guideline

  3. HIV testing: increasing uptake in black Africans (PH33)

    This guidance has been updated and replaced by NICE guideline NG60.

    Withdrawn guideline

  4. HIV testing: increasing uptake in men who have sex with men (PH34)

    This guideline has been updated and replaced by NICE guideline NG60.

    Withdrawn guideline

  5. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline has been updated and replaced by NICE guideline NG246.

    Withdrawn guideline

  6. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG641)

    This guidance has been updated and replaced by HealthTech guidance 639.

    Withdrawn guidance

  7. Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine (IPG559)

    This guidance has been updated and replaced by NICE HealthTech guidance 643.

    Withdrawn guidance

  8. Endoluminal gastroplication for gastro-oesophageal reflux disease (IPG404)

    Interventional procedures, IPG404 - Issued: July 2011 --> This guidance has been updated and replaced by NICE HealthTech guidance 661.

    Withdrawn guidance

  9. Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension (IPG418)

    Interventional procedures, IPG418 - Issued: January 2012 --> This guidance has been updated and replaced by NICE HealthTech guidance 662.

    Withdrawn guidance

  10. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    Discontinued Reference number: GID-TA11302

    Technology appraisal guidance
    Discontinued

  11. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    Discontinued Reference number: GID-TA10598

    Technology appraisal guidance
    Discontinued

  12. Colon cancer (adjuvant) - irinotecan [ID379]

    Discontinued Reference number: GID-TAG380

    Technology appraisal guidance
    Discontinued

  13. Diabetic retinopathy - ruboxistaurin [ID382]

    Discontinued Reference number: GID-TAG386

    Technology appraisal guidance
    Discontinued

  14. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    Discontinued Reference number: GID-TA10779

    Technology appraisal guidance
    Discontinued

  15. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    Discontinued Reference number: GID-TA10822

    Technology appraisal guidance
    Discontinued